State of New Jersey Common Pension Fund D Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

State of New Jersey Common Pension Fund D raised its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 150,291 shares of the medical device company's stock after purchasing an additional 8,668 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in DexCom were worth $10,076,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Crossmark Global Holdings Inc. grew its holdings in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company's stock worth $1,259,000 after acquiring an additional 182 shares during the period. Covestor Ltd boosted its position in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after purchasing an additional 335 shares during the last quarter. Acorn Financial Advisory Services Inc. ADV increased its position in shares of DexCom by 14.4% during the 3rd quarter. Acorn Financial Advisory Services Inc. ADV now owns 14,399 shares of the medical device company's stock valued at $965,000 after purchasing an additional 1,814 shares during the last quarter. CWA Asset Management Group LLC bought a new position in shares of DexCom in the 3rd quarter worth approximately $222,000. Finally, Comprehensive Financial Consultants Institutional Inc. boosted its holdings in shares of DexCom by 13.5% in the third quarter. Comprehensive Financial Consultants Institutional Inc. now owns 7,334 shares of the medical device company's stock worth $492,000 after buying an additional 874 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DexCom stock traded up $0.35 during trading hours on Monday, reaching $70.31. The company's stock had a trading volume of 4,531,853 shares, compared to its average volume of 3,910,189. The firm has a 50 day moving average price of $69.66 and a 200-day moving average price of $93.10. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market cap of $27.46 billion, a P/E ratio of 42.54, a P/E/G ratio of 2.15 and a beta of 1.17. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company's stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on DXCM. Baird R W downgraded shares of DexCom from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 26th. Robert W. Baird boosted their price target on DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, August 5th. Wells Fargo & Company lifted their price objective on DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. Leerink Partners lowered their price objective on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, Oppenheimer decreased their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.